<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933294</url>
  </required_header>
  <id_info>
    <org_study_id>ZLYXXTCX-201509</org_study_id>
    <nct_id>NCT02933294</nct_id>
  </id_info>
  <brief_title>Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer</brief_title>
  <official_title>Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer: a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is one of the most common cancers in the world. At present, surgical resection is&#xD;
      still the standard treatment for early stage lung cancer. Triportal thoracoscopic lung&#xD;
      resection is a routine surgically procedure for early stage lung cancer while uniportal&#xD;
      thoracoscopic lung resection is developing rapidly in recent years. Although uniportal VATS&#xD;
      pulmonary resection has been proven to be effective in preventing postoperative morbidities,&#xD;
      there is still no ample evidences to demonstrate that uniportal VATS pulmonary resection is&#xD;
      equal or superior to traditional triportal thoracoscopic pulmonary resection. The purpose of&#xD;
      this multicenter randomized controlled trial study is to compare the uniportal VATS with&#xD;
      traditional triportal VATS pulmonary resection in postoperative complications, long-term&#xD;
      survival, lymph node dissection and local recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is one of the most common cancers in the world，especially in China, where the&#xD;
      mortality ranked first in malignant tumors whether for males or females. At present, VATS&#xD;
      (Video-assisted thoracoscopic surgery) lobectomy is still the &quot;gold standard&quot; for the&#xD;
      treatment of lung cancer. Triportal thoracoscopic lung resection is a routine surgically&#xD;
      procedure for early stage lung cancer while uniportal thoracoscopic lung resection is&#xD;
      developing rapidly in recent years. Retrospective study in recent years showed that the&#xD;
      postoperative complication rate is similar between uniportal thoracoscopic surgery and&#xD;
      triportal thoracoscopic surgery. Meanwhile, the incision is more pleasing, the inflammatory&#xD;
      response may be milder and the hospitalization time may be shorter in the uniportal&#xD;
      thoracoscopic surgery. But until now there is no result of the randomized controlled study on&#xD;
      the effectiveness and the prognosis between uniportal thoracoscopic surgery and triportal&#xD;
      thoracoscopic surgery to support this conclusion. The objective of this multicenter&#xD;
      randomized controlled trial study is to compare the postoperative complications, long-term&#xD;
      survival, local recurrence, other perioperative variables such as conversion rate, blood&#xD;
      loss, lymph nodes retrieved and postoperative hospital stay between the triportal VATS&#xD;
      pulmonary resection and uniportal VATS pulmonary resection on early stage lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative respiratory complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>These respiratory complications involve respiratory distress or failure after the operation with continuation of mechanical ventilation, pulmonary atelectasis requiring sputum suction by bronchoscopy, pneumonia requiring specific antibiotics confirmed by thoracic X-ray or CT scan of the thorax and a positive sputum culture, and acute respiratory distress syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Intraoperation</time_frame>
    <description>blood loss during the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node dissection</measure>
    <time_frame>Intraoperation</time_frame>
    <description>During the surgery, lymph node dissection were performed. The number of removed lymph-nodes were recorded according to the postoperative pathological diagnosis, and the stations of the lymph node were recorded according to the International Association for the Study of Lung Cancer (IASLC) Lymph Node Map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term survival</measure>
    <time_frame>5 year</time_frame>
    <description>five-year survival rates after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>three-year local recurrence rate after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate</measure>
    <time_frame>Intraoperation</time_frame>
    <description>conversion to thoracotomy during surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Triportal pulmonary resection surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uniportal pulmonary resection surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Triportal pulmonary resection surgery</intervention_name>
    <description>Uniportal video-assisted thoracoscopic surgery</description>
    <arm_group_label>Triportal pulmonary resection surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Uniportal pulmonary resection surgery</intervention_name>
    <description>Triportal video-assisted thoracoscopic surgery</description>
    <arm_group_label>Uniportal pulmonary resection surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age≥18 years;&#xD;
&#xD;
          -  cT1- 2N0-1M0 diagnosed by chest CT, PET-CT before operation;&#xD;
&#xD;
          -  No severe comorbidity, can tolerate anesthesia;&#xD;
&#xD;
          -  ECOG PS scores≤2;&#xD;
&#xD;
          -  The patients sign informed consents by themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to tolerance of tracheal intubation and general anesthesia;&#xD;
&#xD;
          -  ECOG PS scores&gt;2;&#xD;
&#xD;
          -  Severe comorbidities including: Angina occurs in 3 months, uncontrolled hypertension,&#xD;
             Congestive heart failure, a history of myocardial infarction in 6 months before&#xD;
             admission, severe arrhythmia, severe liver, kidney or other metabolic diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juwei Mu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Innovation Center for Cancer Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juwei Mu, MD</last_name>
    <phone>8610-87788495</phone>
    <phone_ext>7140</phone_ext>
    <email>mujuwei@cicams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanjun Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhidong Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaqing Xiang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ju-Wei Mu</investigator_full_name>
    <investigator_title>MD，PHD</investigator_title>
  </responsible_party>
  <keyword>uniportal</keyword>
  <keyword>lung cancer</keyword>
  <keyword>VATS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

